Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-07-08
2008-07-08
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S252130, C514S253010, C514S254020, C514S254050, C514S255040, C514S254010, C544S360000, C544S363000, C544S369000, C544S370000, C544S372000, C544S379000, C544S396000
Reexamination Certificate
active
10533744
ABSTRACT:
Compounds of general formula: wherein R1and R2are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.
REFERENCES:
patent: 3940386 (1976-02-01), Szabo et al.
patent: 4778789 (1988-10-01), Fex et al.
patent: 5574159 (1996-11-01), Chang et al.
patent: 5658908 (1997-08-01), Chang et al.
patent: 5681830 (1997-10-01), Chang et al.
patent: 5807858 (1998-09-01), Chang et al.
patent: 5840896 (1998-11-01), Van Belle et al.
patent: 5854249 (1998-12-01), Chang et al.
patent: 6130222 (2000-10-01), Roberts et al.
patent: 6680318 (2004-01-01), Brown et al.
patent: 6680321 (2004-01-01), Roberts et al.
patent: 6696447 (2004-02-01), Brown et al.
patent: 6784181 (2004-08-01), Brown et al.
patent: 7030124 (2006-04-01), Chang et al.
patent: 2006/0030569 (2006-02-01), Brown et al.
patent: 2431178 (1975-01-01), None
patent: 2900810 (1980-07-01), None
patent: 0133323 (1985-02-01), None
patent: 0166302 (1986-01-01), None
patent: 0283310 (1988-09-01), None
patent: 0289227 (1988-11-01), None
patent: 0624584 (1998-08-01), None
patent: 2696744 (1994-04-01), None
patent: 2076403 (1981-12-01), None
patent: 2210366 (1989-06-01), None
patent: 215847 (1999-04-01), None
patent: 217619 (2000-03-01), None
patent: 7-138230 (1995-05-01), None
patent: 7138230 (1995-05-01), None
patent: WO 86/04584 (1986-08-01), None
patent: WO 91/07967 (1991-06-01), None
patent: WO 92/04338 (1992-03-01), None
patent: 9206971 (1992-04-01), None
patent: WO 93/15062 (1993-08-01), None
patent: WO 95/04051 (1995-02-01), None
patent: 9626196 (1996-08-01), None
patent: WO 97/23466 (1997-07-01), None
patent: WO 98/28270 (1998-07-01), None
patent: WO 98/28275 (1998-07-01), None
patent: WO 99/33806 (1999-07-01), None
patent: 0146263 (2001-06-01), None
patent: WO 01/45637 (2001-06-01), None
patent: WO 01/46174 (2001-06-01), None
patent: WO 01/74805 (2001-10-01), None
patent: 02094786 (2002-11-01), None
patent: 02094812 (2002-11-01), None
patent: WO 02/094794 (2002-11-01), None
patent: WO 03/029215 (2003-04-01), None
patent: 03094853 (2003-11-01), None
patent: 2004041802 (2004-05-01), None
patent: WO 2004/041800 (2004-05-01), None
patent: WO 2004/041801 (2004-05-01), None
patent: 2004062562 (2004-07-01), None
patent: WO 2005/066148 (2005-07-01), None
patent: 2006014133 (2006-02-01), None
patent: 2006091160 (2006-08-01), None
U.S. Appl. No. 10/714,447, filed Nov. 17, 2003.
U.S. Appl. No. 10/477,642, a PCT national phase filed May 16, 2002.
U.S. Appl. No. 10/533,654, a PCT national phase filed Nov. 5, 2003.
U.S. Appl. No. 10/533,764, a PCT national phase filed Nov. 5, 2003
Bilsky et al., “SNC 80, A Selective, Nonpeptidic and Systemically Active Opioid Delta Agonist,” J. Pharmacol. Experi. Ther. 273:359-366 (1995).
Takemori et al., “Selective Natrexone-Drived Opioid Receptor Antagonists,” Annu. Rev. Pharmacol. Toxicol. 32:239-269 (1992).
Bilsky et al., “Characterization of Enantiomers of (+) BW373U86 and Related Compounds: Highly Selective Non-Peptidic Delta Opioid Agonists,” Reg. Peptides 54:25-26 (1994).
Calderon et al., “Probes for Narcotic Receptor Mediated Phenomena. 19. Synthesis of . . . Opioid Receptor Agonist,” J. Med. Chem. 37:2125-2128 (1994).
Calderon et al., “Probes for Narcotic Receptor Mediated Phenomena. 23. Synthesis . . . Opioid Receptor Ligands,” J. Med. Chem. 40:695-704 (1997).
Chang et al., “A Novel, Potent and Selective Nonpeptidic Delta Opioid Receptor Agonist BW373U86,” J. Pharmacol. Exper. Therap. 267:852-857 (1993).
Katrizky et al., “Benzotriazole-Mediated Arylalkylation and Heteroarylalkylation,” Chem. Soc. Rev. 23:363-373 (1994).
Kingsbury et al., “Synthesis of Structural Analogs of Leukotriene B and their Receptor Binding Activity,” J. Med. Chem. 36:3308-3320 (1993).
Lopez et al., “Exploring the Structure-Activity Relationships . . . Opioid Receptor Nonpeptide Agonist Ligand,” J. Med. Chem. 42:5359-5368 (1999).
Plobeck et al., “New Diarylmethylpiperazines as Potent and Selective Nonpeptidic Opioid Receptor Agonists with Increased In Vitro Metabolic Stability,” J. Med. Chem. 43:3878-3894 (2000).
Suggs et al., “Facile Synthesis fo 8-Substituted Quinolines,” J. Org. Chem., 45:1514-1515 (1980).
Zhang et al., “Probes for Narcotic Receptor Mediated Phenomena. 26. Synthesis . . . Opioid Receptor Ligands,” J. Med. Chem. 42:5455-5463 (1999).
English Abstract for FR2696744, (1994).
English Abstract for DE2431178, (1975).
English Abstract for DE2900810, (1980).
English Abstract for JP07138230, (1995).
Burkey et al., “The Efficacy of Delta-Opioid Receptor-Selective Drugs,” Medline Abstract for Life Sci. 62:1531-1536 (1998).
Nagase et al., “The Pharmacological Profile of Delta Opioid Receptor Ligands, (+) and (−) TAN-67 on Pain Modulation,” Medline Abstract for Life Sci. 68:2227-2231 (2001).
Green, “Protective Groups in Organic Synthesis,” pp. 267-268 and 331 (1981).
Abstract for HU 217619, (2000).
Abstract for HU 215847, (1999).
Nortey et al., “Piperazinyl Benzamidines: Synthesis and Affinity for the Delta Opioid Receptor,” Bioorganic & Medicinal Chemistry Letters, vol. 11, pp. 1741-1743 (2001).
Snyder et al., “Historical Review: Opioid Receptors,” Trends in Pharmacological Sciences, vol. 24, pp. 198-205 (2003).
Adriaensen, H. et al., “Clinical Review of Oral Drug Treatments for Diabetic Neuropathic Pain-Clinical Outcomes Based on Efficacy and Safety Data from Placebo-Controlled and Direct Comparative Studies,” Diabetes Metab. Res. Rev., 2005, 21(3), pp. 231-240.
Banker, G. et al., “Modern Pharmaceutics, 3ed.”, Marcel Dekker, New York, 1996, pp. 451 and 596.
Davis, MP et al., “Controversies in Pharmacotherapy of Pain Management,” Lancet Oncol., 2005, 6(9), pp. 696-704.
Filliol, D. et al., “Mice deficient for delta- and mu-opioid receptors exhibit opposing alternations of emotional responses,” Nature Genetics, 2000, vol. 25, pp. 195-200.
Przewlocki, R. et al., “Opioids in Neuropathic Pain,” Curr. Pharm. Des. 2005, 11(23), pp. 3013-3025.
Saitoch, A., “Potential anxiolytic and antidepressant-like activities of SNC80, a selective delta-opioid agonist, in behavorial models in rodents,” J. Pharmacol. Sci., 2004, vol. 95, pp. 374-380.
Vippagunta, S. et al., “Crystalline Solids,” Advanced Drug Delivery Reviews, 2001, vol. 48, pp. 3-26.
West, A., “Solid State Chemistry and its Applications,” Wiley, New York, 1988, pp. 358 & 365.
Wolff, M., “Burger's Medicinal Chemistry and Drug Discovery, 5ed, Part 1,” John Wiley & Sons, 1995, pp. 975-977.
International Search Report issued for PCT/SE03/01703 on Feb. 24, 2004.
Non-final Office Action issued for U.S. Appl. No. 10/714,447, filed Sep. 10, 2004.
Final Office Action issued for U.S. Appl. No. 10/714,447, filed Mar. 22, 2005.
Advisory Action issued for U.S. Appl. No. 10/714,447, filed Jul. 5, 2005.
Non-final Office Action issued for U.S. Appl. No. 10/714,447, filed Sep. 9, 2005.
Final Office Action issued for U.S. Appl. No. 10/714,447, filed Feb. 16, 2006.
Non-final Office Action issued for U.S. Appl. No. 10/477,642, filed Jan. 13, 2005.
Non-final Office Action issued for U.S. Appl. No. 10/477,642, filed Jun. 15, 2005.
Final Office Action issued for U.S. Appl. No. 10/477,642, filed Nov. 25, 2005.
Non-final Office Action issued for U.S. Appl. No. 10/477,642, filed Apr. 6, 2006.
Non-final Office Action issued for U.S. Appl. No. 10/533,654, filed Apr. 25, 2006.
Non-final Office Action issued for U.S. Appl. No. 10/533,654, filed Dec. 1, 2006.
Non-final Office Action issued for U.S. Appl. No. 10/533,764, filed Apr. 17, 2006.
Final Office Action issued for U.S. Appl. No. 10/533,764, filed Oct. 2, 2006.
Advisory Action issued for U.S. Appl. No. 10/533,764, filed Jan. 1
Brown William
Griffin Andrew
Plobeck Niklas
Walpole Christopher
AstraZeneca AB
Bernhardt Emily
Cohen Jacqueline M.
LandOfFree
4(Phenyl-piperazinyl-methyl) benzamide derivatives and their... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 4(Phenyl-piperazinyl-methyl) benzamide derivatives and their..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 4(Phenyl-piperazinyl-methyl) benzamide derivatives and their... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3941965